RxDoctor Payments Data

David Mercer, MD

Transplant Surgery · Omaha, NENPI 1104933878

Payments from drug & device makers

$1,208,365in general payments, 2019–2025

Across 204 payments — averaging $5923.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zealand Pharma A/s$770K
  • Shire North American Group Inc$168K
  • Takeda Pharmaceuticals U.S.A., Inc.$143K
  • Vectivbio AG$128K
  • BD$230
  • W. L. Gore & Associates, Inc.$134
  • plus $493 from 5 others

What the payments were for

  • Consulting fees$46,61275%
  • Speaking & faculty fees$9,29215%
  • Travel & lodging$3,8996%
  • Food & beverage$2,2724%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant surgery providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$68,244
Medicare patients
86
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide45$2,328,398
Sodium Chloride0.9 % Sodium Chloride194$8,244
Vancomycin Hcl122$5,423
Sodium Chloride24$2,727
Daptomycin29$2,218
Potassium Chloride20$1,615
Gentamicin SulfateGentamicin Sulfate/Pf78$1,476
Magnesium Sulfate12$975
Ondansetron OdtOndansetron20$840
LoperamideLoperamide Hcl18$526
Dextrose 5%-0.45% NaclDextrose 5 %-0.45 % Sod Chlord12$507
Sodium ChlorideSodium Chloride 0.45 %12$386
Famotidine19$355
Pantoprazole Sodium25$194
Sulfasalazine14$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$142,551$2,328,39845 claims
Fresenius Kabi USA, LLCSodium Chloride, Sodium Chloride, Magnesium Sulfate, Sodium Chloride$122$12,333242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few transplant surgery providers in Nebraskaon file to place this against a meaningful peer group, so we don't.

Other transplant surgery in Omaha

Where these figures come from

Is this you, or does something look wrong? →